Get started
SOLIGENIX INC COM USD0.001(POST REV SPLT)SOLIGENIX INC COM USD0.001(POST REV SPLT)SOLIGENIX INC COM USD0.001(POST REV SPLT)

SOLIGENIX INC COM USD0.001(POST REV SPLT)

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

0A6I trade ideas

SNGX Potential Entry VWAP Support/50% RetraceSee link in comments for my coverage of this stock from 5/20. Stock has made it's move higher, gap filled and has found support at the 50% retracement level. Consolidation is occurring above a rising 50 EMA and the VWAP from the 2/20 peak. I would look for stock to reclaim 5 day EMA (orange) to initiate position. I have to expect further upside unless price breaks below 50 EMA or VWAP, which would force me to revise my outlook. Company has 2 Phase III drugs, with one announcement coming Q4 this year. Company has no products on the market. For press releases and pipeline info: www.biopharmcatalyst.com
NASDAQ:SNGXLong
by ETrades1
SNGX Wedge + SMA ConvergencePrice finding support above July '19 high. Strong momentum setup: OBV has set a new high, RSI showing bullish divergence while MACD has begun to accelerate. Very bullish MA convergence with 5 and 20 pushing through the 50 with upside trajectory. Notice prior move higher in late 2019 occurred subsequently to 200 MA support. Ideally I am looking for a breakout of wedge, pullback and potentially waiting for a reclaiming of the 5 day MA to initiate a position, but I believe the indicators convey strong underlying momentum so I may just have to ride the wave on this one. $2.3 - $2.5 looks like a good area to consider taking some off the table.
NASDAQ:SNGXLong
by ETrades1
Soligenix, Inc Breakout TradeSoligenix, Inc. engages in the development and commercialization of products to treat rare disease. It operates through the following segments: BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Vaccines/BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.
NASDAQ:SNGXLong
by DEXWireNews